Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Statistical Analysis
3. Results
3.1. Resection Rate/Portal Vein Resection and Arterial Resection Rate/Residual Tumor Rate According to the Resectability Status
3.2. Total Survival, RFS, and OS of Resection Cases
3.3. Predictive Factors for RFS and OS in Patients Who Underwent Surgery
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Fujii, T.; Sugimoto, H.; Yamada, S.; Kanda, M.; Suenaga, M.; Takami, H.; Hattori, M.; Inokawa, Y.; Nomoto, S.; Fujiwara, M.; et al. Modified Blumgart anastomosis for pancreaticojejunostomy: Technical improvement in matched historical control study. J. Gastrointest. Surg. 2014, 18, 1108–1115. [Google Scholar] [CrossRef]
- Ratnayake, B.; Al-Leswas, D.; Mohammadi-Zaniani, G.; Littler, P.; Sen, G.; Manas, D.; Pandanaboyana, S. Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review. Cancers 2021, 13, 3212. [Google Scholar] [CrossRef]
- Kawaida, H.; Kono, H.; Hosomura, N.; Amemiya, H.; Itakura, J.; Fujii, H.; Ichikawa, D. Surgical techniques and postoperative management to prevent postoperative pancreatic fistula after pancreatic surgery. World J. Gastroenterol. 2019, 25, 3722–3737. [Google Scholar] [CrossRef]
- Heinrich, S.; Lang, H. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. Int. J. Mol. Sci. 2017, 18, 1622. [Google Scholar] [CrossRef]
- Fujii, T.; Yamada, S.; Murotani, K.; Kanda, M.; Sugimoto, H.; Nakao, A.; Kodera, Y. Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment. Medicine 2015, 94, e1647. [Google Scholar] [CrossRef] [PubMed]
- Uesaka, K.; Boku, N.; Fukutomi, A.; Okamura, Y.; Konishi, M.; Matsumoto, I.; Kaneoka, Y.; Shimizu, Y.; Nakamori, S.; Sakamoto, H.; et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016, 388, 248–257. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer Statistics, 2021. CA A Cancer J. Clin. 2021, 71, 7–33. [Google Scholar] [CrossRef]
- Tempero, M.A.; Malafa, M.P.; Al-Hawary, M.; Asbun, H.; Bain, A.; Behrman, S.W.; Benson, A.B., III; Binder, E.; Cardin, D.B.; Cha, C.; et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2017, 15, 1028–1061. [Google Scholar] [CrossRef]
- Neoptolemos, J.P.; Stocken, D.D.; Friess, H.; Bassi, C.; Dunn, J.A.; Hickey, H.; Beger, H.; Fernandez-Cruz, L.; Dervenis, C.; Lacaine, F.; et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 2004, 350, 1200–1210. [Google Scholar] [CrossRef]
- Motoi, F.; Kosuge, T.; Ueno, H.; Yamaue, H.; Satoi, S.; Sho, M.; Honda, G.; Matsumoto, I.; Wada, K.; Furuse, J.; et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn. J. Clin. Oncol. 2019, 49, 190–194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Conroy, T.; Desseigne, F.; Ychou, M.; Bouche, O.; Guimbaud, R.; Becouarn, Y.; Adenis, A.; Raoul, J.L.; Gourgou-Bourgade, S.; de la Fouchardiere, C.; et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364, 1817–1825. [Google Scholar] [CrossRef]
- Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 2013, 369, 1691–1703. [Google Scholar] [CrossRef] [PubMed]
- Wang-Gillam, A.; Li, C.P.; Bodoky, G.; Dean, A.; Shan, Y.S.; Jameson, G.; Macarulla, T.; Lee, K.H.; Cunningham, D.; Blanc, J.F.; et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial. Lancet 2016, 387, 545–557. [Google Scholar] [CrossRef] [PubMed]
- Kimura, Y.; Nakamura, T.; Hayashi, T.; Kuwatani, M.; Motoya, M.; Yoshida, M.; Imamura, M.; Nagayama, M.; Yamaguchi, H.; Yamakita, K.; et al. Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01). Ann. Gastroenterol. Surg. 2019, 3, 523–533. [Google Scholar] [CrossRef] [PubMed]
- Hackert, T.; Sachsenmaier, M.; Hinz, U.; Schneider, L.; Michalski, C.W.; Springfeld, C.; Strobel, O.; Jager, D.; Ulrich, A.; Buchler, M.W. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann. Surg. 2016, 264, 457–463. [Google Scholar] [CrossRef]
- Napolitano, F.; Formisano, L.; Giardino, A.; Girelli, R.; Servetto, A.; Santaniello, A.; Foschini, F.; Marciano, R.; Mozzillo, E.; Carratu, A.C.; et al. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers 2019, 11, 981. [Google Scholar] [CrossRef] [PubMed]
- Satoi, S.; Yamaue, H.; Kato, K.; Takahashi, S.; Hirono, S.; Takeda, S.; Eguchi, H.; Sho, M.; Wada, K.; Shinchi, H.; et al. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J. Hepato-Biliary-Pancreat. Sci. 2013, 20, 590–600. [Google Scholar] [CrossRef]
- Mataki, Y.; Kurahara, H.; Idichi, T.; Tanoue, K.; Hozaka, Y.; Kawasaki, Y.; Iino, S.; Maemura, K.; Shinchi, H.; Ohtsuka, T. Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis. Cancers 2021, 13, 1057. [Google Scholar] [CrossRef]
- Takada, R.; Ikezawa, K.; Daiku, K.; Maeda, S.; Abe, Y.; Urabe, M.; Kai, Y.; Yamai, T.; Fukutake, N.; Nakabori, T.; et al. The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer. Cancers 2021, 13, 4733. [Google Scholar] [CrossRef]
- Kobayashi, K.; Einama, T.; Takihata, Y.; Yonamine, N.; Fujinuma, I.; Tsunenari, T.; Kouzu, K.; Nakazawa, A.; Iwasaki, T.; Ueno, H.; et al. Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: A retrospective study. BMC Cancer 2022, 22, 1028. [Google Scholar] [CrossRef]
- Gemenetzis, G.; Groot, V.P.; Blair, A.B.; Laheru, D.A.; Zheng, L.; Narang, A.K.; Fishman, E.K.; Hruban, R.H.; Yu, J.; Burkhart, R.A.; et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann. Surg. 2019, 270, 340–347. [Google Scholar] [CrossRef] [PubMed]
- Yanagimoto, H.; Satoi, S.; Yamamoto, T.; Yamaki, S.; Hirooka, S.; Kotsuka, M.; Ryota, H.; Ishida, M.; Matsui, Y.; Sekimoto, M. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Cancers 2020, 12, 1428. [Google Scholar] [CrossRef] [PubMed]
- Yamaguchi, J.; Yokoyama, Y.; Fujii, T.; Yamada, S.; Takami, H.; Kawashima, H.; Ohno, E.; Ishikawa, T.; Maeda, O.; Ogawa, H.; et al. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01). Ann. Surg. 2022, 275, 1043–1049. [Google Scholar] [CrossRef] [PubMed]
- Iwasa, S.; Yamada, Y.; Fukagawa, T.; Eguchi Nakajima, T.; Kato, K.; Hamaguchi, T.; Morita, S.; Saka, M.; Katai, H.; Shimada, Y. Management of adjuvant S-1 therapy after curative resection of gastric cancer: Dose reduction and treatment schedule modification. Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 2011, 14, 28–34. [Google Scholar] [CrossRef] [PubMed]
- Callery, M.P.; Chang, K.J.; Fishman, E.K.; Talamonti, M.S.; William Traverso, L.; Linehan, D.C. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann. Surg. Oncol. 2009, 16, 1727–1733. [Google Scholar] [CrossRef]
- Isaji, S.; Mizuno, S.; Windsor, J.A.; Bassi, C.; Fernandez-Del Castillo, C.; Hackert, T.; Hayasaki, A.; Katz, M.H.G.; Kim, S.W.; Kishiwada, M.; et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018, 18, 2–11. [Google Scholar] [CrossRef]
- Einama, T.; Kamachi, H.; Tsuruga, Y.; Sakata, T.; Shibuya, K.; Sakamoto, Y.; Shimada, S.; Wakayama, K.; Orimo, T.; Yokoo, H.; et al. Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma. Medicine 2018, 97, e11309. [Google Scholar] [CrossRef]
- Bickenbach, K.A.; Gonen, M.; Tang, L.H.; O’Reilly, E.; Goodman, K.; Brennan, M.F.; D’Angelica, M.I.; Dematteo, R.P.; Fong, Y.; Jarnagin, W.R.; et al. Downstaging in pancreatic cancer: A matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann. Surg. Oncol. 2012, 19, 1663–1669. [Google Scholar] [CrossRef]
- Tomasello, G.; Ghidini, M.; Ghidini, A.; Trevisan, F.; Celotti, A.; Russo, A.; Gambini, D.; Indini, A.; Rijavec, E.; Bareggi, C.; et al. Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol. 2021, 164, 13–19. [Google Scholar] [CrossRef]
- Pusceddu, S.; Ghidini, M.; Torchio, M.; Corti, F.; Tomasello, G.; Niger, M.; Prinzi, N.; Nichetti, F.; Coinu, A.; Di Bartolomeo, M.; et al. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers 2019, 11, 484. [Google Scholar] [CrossRef] [Green Version]
Univariate | Multivariate | |||
---|---|---|---|---|
Parameter (Unfavorable vs. Favorable) | HR (95% CI) | p-Value | HR (95% CI) | p-Value |
Pathological T-factor | 3.61 | 0.0248 | 2.87 | 0.236 |
(T3,4 vs. T1,2) | (1.14–87.4) | (0.57–52.16) | ||
Pathological N-factor | 3.53 | <0.0001 | 3.959 | 0.0002 |
(Positive vs. Negative) | (1.87–7.56) | (1.83–10.00) | ||
Lymphatic permeation | 2.99 | 0.0011 | 1.14 | 0.767 |
(Positive vs. Negative) | (1.49–7.12) | (0.44–2.50) | ||
Residual tumor | 1.98 | 0.0194 | 1.52 | 0.156 |
(R1 > R0) | (1.12–3.29) | (0.84–2.61) | ||
Completed adjuvant chemotherapy | 2.47 | <0.0001 | 2.82 | <0.0001 |
(No > Yes) | (1.62–3.80) | (1.81–4.46) | ||
Resectability | 0.1088 | |||
(BR + UR vs. R) | (0.44–1.09) |
Univariate | Multivariate | |||
---|---|---|---|---|
Parameter (Unfavorable vs. Favorable) | HR (95% CI) | p-Value | HR (95% CI) | p-Value |
Pathological T-factor | 2.68 | 0.168 | ||
(T3,4 vs. T1,2) | (0.85–16.30) | |||
Pathological N-factor | 2.69 | 0.0010 | 3.24 | 0.0012 |
(Positive vs. Negative) | (1.44–5.57) | (1.54–7.79) | ||
Lymphatic permeation | 2.43 | 0.0106 | 1.029 | 0.948 |
(Positive vs. Negative) | (1.21–5.81) | (0.409–2.23) | ||
Residual tumor | 1.96 | 0.0147 | 1.69 | 0.0724 |
(R1 > R0) | (1.15–3.18) | (0.95–2.87) | ||
Completed adjuvant chemotherapy | 2.54 | <0.0001 | 2.88 | <0.0001 |
(No > Yes) | (1.62–4.07) | (1.81–4.66) | ||
Resectability | 1.12 | 0.622 | ||
(BR + UR vs. R) | (0.693–1.761) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Einama, T.; Takihata, Y.; Aosasa, S.; Konno, F.; Kobayashi, K.; Yonamine, N.; Fujinuma, I.; Tsunenari, T.; Nakazawa, A.; Shinto, E.; et al. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience. Cancers 2023, 15, 1101. https://doi.org/10.3390/cancers15041101
Einama T, Takihata Y, Aosasa S, Konno F, Kobayashi K, Yonamine N, Fujinuma I, Tsunenari T, Nakazawa A, Shinto E, et al. Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience. Cancers. 2023; 15(4):1101. https://doi.org/10.3390/cancers15041101
Chicago/Turabian StyleEinama, Takahiro, Yasuhiro Takihata, Suefumi Aosasa, Fukumi Konno, Kazuki Kobayashi, Naoto Yonamine, Ibuki Fujinuma, Takazumi Tsunenari, Akiko Nakazawa, Eiji Shinto, and et al. 2023. "Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience" Cancers 15, no. 4: 1101. https://doi.org/10.3390/cancers15041101